Assessment of disease activity in ulcerative colitis using indium-111-labelled leukocyte faecal excretion.
A new method of assessing disease activity in ulcerative colitis has been developed utilizing indium-111-labelled granulocytes. Faecal 111In excretion after intravenous administration of labelled granulocytes ranged from 1.1% to 45% of the injected dose in patients with ulcerative colitis, showing significant differences between mild, moderate, and severely active groups. There was a significant correlation between faecal 111In excretion and a clinical index based on the Crohn's disease activity index (r = 0.79, p less than 0.001) and the erythrocyte sedimentation rate (r = 0.73, p less than 0.001). Quantitative faecal 111In-labelled granulocyte excretion is an objective and specific method of assessing disease activity in ulcerative colitis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001799:Blood Sedimentation; D003093:Colitis, Ulcerative / Q000175:diagnosis*; D005243:Feces / Q000032:analysis*; D005260:Female; D006098:Granulocytes / Q000032:analysis*; D006801:Humans; D007204:Indium; D007962:Leukocytes / Q000032:analysis; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011868:Radioisotopes
D011868:Radioisotopes; D007204:Indium